Results

University of Michigan Health System

12/06/2018 | News release | Distributed by Public on 12/06/2018 19:30

Brain Cancer Patient Finds Hope with Emerging New Therapy

SEE ALSO: Pilot and Marathoner Accelerates Life After Brain Tumor Surgery

A devastating diagnosis

'Two weeks later came the result of the biopsy,' recalls Wetzel. 'I had a malignant brain tumor - known as H3K27M-mutant diffuse midline glioma. Itwas inoperable because of the location near my brainstem.'

'Diffuse midline glioma, H3K27M-mutant, WHO grade 4, is an extremely rare tumor with no known cure,' says radiation-oncologist Kim. 'Surgical resection is usually not possible, and the mainstay of treatment has historically been radiation therapy.'

MORE FROM MICHIGAN: Sign up for our weekly newsletter

Wetzel shared the devastating news with her family, who flew from Beaver Island, Michigan, a small island in Lake Michigan where she had grown up. Wetzel had been one of only five students in her high school graduating class.

Together, her close-knit family kept an optimistic outlook, gathering as much information as possible about the condition and available treatment options.

Her decision: a six-week combination of radiation, chemotherapy and steroids that began last February.Despite the aggressive therapy, however, her tumor continued to grow rapidly.

'Glimmers of promise'

After looking into novel treatment options based on the tumor's genetic mutations, Wetzel's Michigan Medicine care team suggested ONC201, an emerging new drug. ONC201 acts by blocking the molecular pathways that drive cancer cell growth. The drug is currently in clinical trials for pediatric and adult patients and is showing 'glimmers of promise,' says neuro-oncologist Umemura.

Wetzel was not able to enroll in any existing ONC201 clinical trials, but with special permission granted by drugmaker Oncoceutics and the FDA, as well as approval by Michigan Medicine's Institutional Review Board, she would become the first adult brain cancer patient at Michigan Medicine to receive ONC201.

'Instead of traditional chemotherapy, the patient has been receiving ONC201 - an oral drug taken once a week - for a few months now, and her tumor has stopped growing,' says Kim.

Holding steady

Kim and Umemura are inspired by Wetzel's acceptance of her condition and her desire to help others with similar diagnoses.

'Caitlin is a very special individual,' says Kim, noting that she was more concerned about helping other brain tumor patients, even while undergoing radiation and chemo treatment for her own tumor. 'She truly views herself as a 'voice' for others.'

Wetzel's attitude and outlook remain positive.

'I'm currently in a holding pattern and have an MRI every nine weeks. It's an aggressive tumor, so no growth is good news,' she says, noting that the tumor likely began to grow a year ago when she experienced the severe headache.

'Holding steady is a good thing for this type of tumor,' says Umemura. 'We could hope for shrinkage of the tumor - it's not out of the question. There have been reported cases of patients with slow tumor shrinkage with ONC201.'

Wetzel's latest MRI, conducted in early November, indicated that the tumor is stable.

Living her life

Wetzel is quick to point out that she hasn't let her tumor change any future plans - an outlook her new husband shares.

'Richard proposed while I was in the hospital,' she says. 'He knelt on the floor near my hospital bed and I didn't even realize he was proposing.'

Wetzel said 'yes' and the two were married a few months later.

The cancer has taught the newlyweds and their families a valuable lesson: Don't sweat the small stuff.

'We don't stress out about every little thing,' says Wetzel, who is happy to be living in the country with two dogs, her husband and plenty of wide-open space.

'Caitlin's tumor remains stable and her attitude is good,' says Umemura. 'This tumor hasn't stopped her from living her life.'

Kim agrees: 'When you meet people like her, it reminds you of why you even became a doctor to begin with, and what an honor and privilege it is to share the journey with them.'